MARKET

SRPT

SRPT

Sarepta Therapeutics Inc
NASDAQ
17.82
+0.25
+1.42%
After Hours: 17.82 0 0.00% 19:48 11/06 EST
OPEN
18.77
PREV CLOSE
17.57
HIGH
18.77
LOW
17.52
VOLUME
2.60M
TURNOVER
--
52 WEEK HIGH
24.68
52 WEEK LOW
14.68
MARKET CAP
1.91B
P/E (TTM)
-131.9023
1D
5D
1M
3M
1Y
5Y
1D
Is Sarepta Therapeutics (SRPT) Undervalued Following Raised 2026 Guidance And Mixed Quarterly Results?
Simply Wall St · 1d ago
Analysts Conflicted on These Healthcare Names: Elicio Therapeutics (ELTX), Amphastar Pharmaceuticals (AMPH) and Sarepta Therapeutics (SRPT)
TipRanks · 1d ago
Will Narrower Losses Change Sarepta Therapeutics Stock Narrative
Simply Wall St · 2d ago
Sarepta Therapeutics Is Maintained at Sector Perform by RBC Capital
Dow Jones · 2d ago
Sarepta Therapeutics Price Target Raised to $18.00/Share From $17.00 by RBC Capital
Dow Jones · 2d ago
RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Raises Price Target to $18
Benzinga · 2d ago
Sarepta-Hansa Gene Therapy Study Ends, Raising Questions for Investors
TipRanks · 2d ago
Sarepta (SRPT) Q3 2026 Earnings Call Transcript
The Motley Fool · 2d ago
More
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.

Webull offers Sarepta Therapeutics Inc stock information, including NASDAQ: SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.